Log in

NASDAQ:AMRNAmarin Earnings Date, Estimates & History

+0.08 (+1.20 %)
(As of 07/10/2020 04:00 PM ET)
Today's Range
Now: $6.72
50-Day Range
MA: $6.88
52-Week Range
Now: $6.72
Volume3.32 million shs
Average Volume5.05 million shs
Market Capitalization$2.59 billion
P/E RatioN/A
Dividend YieldN/A


Amarin (NASDAQ:AMRN) Earnings Information

Amarin last issued its earnings data on April 30th, 2020. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.01. The firm had revenue of $155 million for the quarter, compared to analysts' expectations of $150.06 million. Its revenue was up 111.5% compared to the same quarter last year. Amarin has generated ($0.07) earnings per share over the last year. Amarin has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, July 29th, 2020 based off prior year's report dates.

Amarin Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Amarin (NASDAQ:AMRN) Earnings Estimates

2020 EPS Consensus Estimate: ($0.09)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20202($0.05)($0.05)($0.05)
Q2 20202($0.06)($0.04)($0.05)
Q3 20202($0.04)$0.03($0.01)
Q4 20202($0.04)$0.08$0.02

Amarin (NASDAQ AMRN) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
4/30/20203/31/2020($0.07)($0.06)($0.06)$150.06 million$155.00 millionTranscript
2/25/2020Q4 2019($0.02)$0.02$0.02$137.70 million$143.28 millionTranscript
11/5/20199/30/2019($0.04)($0.01)($0.01)$110.04 million$112.40 millionTranscript
7/31/2019Q2($0.02)($0.01)($0.01)$99.54 million$100.40 millionTranscript
5/1/20193/31/2019($0.11)($0.07)($0.07)$67.30 million$73.30 millionN/A
2/27/2019Q4 2018($0.08)($0.11)($0.11)$73.87 million$77.30 millionListen
11/1/20189/30/2018($0.09)($0.08)($0.08)$60.63 million$55.00 millionListen
8/1/20186/30/2018($0.09)($0.12)($0.12)$54.88 million$52.64 millionN/A
5/2/20183/31/2018($0.08)($0.08)($0.08)$43.75 million$43.80 millionN/A
2/27/2018n/a($0.05)($0.08)($0.08)$52.73 million$53.87 millionN/A
11/1/2017Q3 2017($0.05)($0.04)($0.04)$45.85 million$47.10 millionN/A
8/2/20176/30/2017($0.06)($0.05)($0.05)$40.35 million$44.95 millionListen
5/4/20173/31/2017($0.07)($0.08)($0.08)$37.85 million$34.60 millionListen
2/28/2017Q4 2016($0.09)($0.05)$36.13 million$38.40 millionListen
11/3/2016Q316($0.10)($0.08)($0.12)$32.03 million$32.40 millionN/A
8/4/2016Q216($0.13)($0.07)($0.15)$29.97 million$32.82 millionN/A
5/5/2016Q116($0.11)($0.14)($0.14)$26.77 million$25.30 millionN/A
2/25/2016Q415($0.08)($0.12)($0.12)$23.62 million$26.40 millionListen
11/4/2015Q315($0.12)($0.18)($0.18)$21.93 million$21.30 millionN/A
8/6/2015Q2($0.12)($0.15)$0.01$19.10 million$17.70 millionN/A
5/8/2015Q115($0.11)($0.18)($0.18)$21.86 million$15.60 millionN/A
3/3/2015Q414($0.13)($0.11)($0.15)$17.40 million$16.50 millionN/A
11/6/2014Q314($0.14)($0.18)($0.19)$14.87 million$14.15 millionN/A
8/7/2014Q214($0.15)($0.14)($0.37)$12.86 million$12.60 millionN/A
5/9/2014Q114($0.18)($0.17)($0.19)$11.65 million$11.00 millionN/A
2/27/2014Q4 2013($0.21)($0.26)($0.43)$11.17 million$10.10 millionTranscript
11/7/2013Q3 2013($0.33)($0.28)($0.27)$10.25 million$8.40 millionN/A
8/8/2013Q2 2013($0.41)($0.39)($0.52)$5.50 millionN/A
5/9/2013Q1 2013($0.36)($0.44)($0.47)$5.21 million$2.34 millionTranscript
2/28/2013Q4 2012($0.28)($0.28)Transcript
8/8/2012Q2 2012($0.15)($0.24)($0.10)N/A
5/8/2012Q1 2012($0.09)($0.15)$0.35N/A
2/29/2012Q4 2011($0.08)($0.08)($0.28)N/A
11/7/2011Q3 2011($0.13)($0.10)($0.82)N/A
8/9/2011Q2 2011($0.12)$2.51$3.44N/A
5/10/2011Q1 2011($0.08)($0.05)($0.22)N/A
3/16/2011Q4 2010($0.08)$0.17$2.16N/A
9/25/2008Q2 2008$0.01$0.01N/A
5/19/2008Q4 2007($0.61)($0.50)N/A
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.